Literature DB >> 28066615

Did dose escalated radiotherapy in stage III non-small cell lung cancer improve overall survival?

Wei-Wei Wang1, Shao-Jia Wang2, Zhi-Rui Zhou3.   

Abstract

Radiotherapy has been applied in the treatment for lung cancer patients for many years, especially those with advanced stage disease who cannot be treated with surgery. However, if these advanced stage patients should be treated with standard dosage therapy (60 Gy) or high dosage therapy (>60 Gy) remains a hot debated point. Literature related to this topic would be reviewed here. We believe standard dosage therapy should be strongly recommended, and high dosage therapy might benefit patients with high risk factors patients.

Entities:  

Keywords:  Non-small cell lung cancer (NSCLC); radiotherapy; review

Year:  2016        PMID: 28066615      PMCID: PMC5179433          DOI: 10.21037/jtd.2016.11.13

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  14 in total

Review 1.  Hyperfractionated and accelerated radiotherapy in non-small cell lung cancer.

Authors:  Kate Haslett; Christoph Pöttgen; Martin Stuschke; Corinne Faivre-Finn
Journal:  J Thorac Dis       Date:  2014-04       Impact factor: 2.895

2.  Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer.

Authors:  Steven E Schild; William L McGinnis; David Graham; Shauna Hillman; Tom R Fitch; Donald Northfelt; Yolanda I Garces; Homayoon Shahidi; Loren K Tschetter; Paul L Schaefer; Alex Adjei; James Jett
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-05-26       Impact factor: 7.038

3.  A meta-analysis comparing hyperfractionated vs. conventional fractionated radiotherapy in non-small cell lung cancer.

Authors:  Weisan Zhang; Qian Liu; Xifeng Dong; Ping Lei
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

4.  Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.

Authors:  Jeffrey Bradley; Mary V Graham; Kathryn Winter; James A Purdy; Ritsuko Komaki; Wilson H Roa; Janice K Ryu; Walter Bosch; Bahman Emami
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-02-01       Impact factor: 7.038

5.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.

Authors:  K Furuse; M Fukuoka; M Kawahara; H Nishikawa; Y Takada; S Kudoh; N Katagami; Y Ariyoshi
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

6.  High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study.

Authors:  Feng-Ming Kong; Randall K Ten Haken; Matthew J Schipper; Molly A Sullivan; Ming Chen; Carlos Lopez; Gregory P Kalemkerian; James A Hayman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-10-01       Impact factor: 7.038

7.  Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.

Authors:  Walter J Curran; Rebecca Paulus; Corey J Langer; Ritsuko Komaki; Jin S Lee; Stephen Hauser; Benjamin Movsas; Todd Wasserman; Seth A Rosenthal; Elizabeth Gore; Mitchell Machtay; William Sause; James D Cox
Journal:  J Natl Cancer Inst       Date:  2011-09-08       Impact factor: 13.506

8.  Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105.

Authors:  Mark A Socinski; A William Blackstock; Jeffrey A Bogart; Xiaofei Wang; Michael Munley; Julian Rosenman; Lin Gu; Gregory A Masters; Peter Ungaro; Arthur Sleeper; Mark Green; Antonius A Miller; Everett E Vokes
Journal:  J Clin Oncol       Date:  2008-05-20       Impact factor: 44.544

9.  Cancer statistics in China, 2015.

Authors:  Wanqing Chen; Rongshou Zheng; Peter D Baade; Siwei Zhang; Hongmei Zeng; Freddie Bray; Ahmedin Jemal; Xue Qin Yu; Jie He
Journal:  CA Cancer J Clin       Date:  2016-01-25       Impact factor: 508.702

10.  The National Cancer Data Base: a powerful initiative to improve cancer care in the United States.

Authors:  Karl Y Bilimoria; Andrew K Stewart; David P Winchester; Clifford Y Ko
Journal:  Ann Surg Oncol       Date:  2008-01-09       Impact factor: 5.344

View more
  2 in total

1.  How much primary tumor metabolic volume reduction is required to improve outcome in stage III NSCLC after chemoradiotherapy? A single-centre experience.

Authors:  Olarn Roengvoraphoj; Chukwuka Eze; Cherylina Wijaya; Maurice Dantes; Julian Taugner; Amanda Tufman; Rudolf Maria Huber; Peter Bartenstein; Claus Belka; Farkhad Manapov
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-06-06       Impact factor: 9.236

2.  Inhibition of protein kinase CK2 sensitizes non-small cell lung cancer cells to cisplatin via upregulation of PML.

Authors:  Bo Yang; Jinhong Yao; Bai Li; Guoguang Shao; Yongsheng Cui
Journal:  Mol Cell Biochem       Date:  2017-07-25       Impact factor: 3.396

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.